Apposite could make more than 20x return from Ulthera exit


skinHealthcare-focused investor Apposite Capital has exited Ulthera with expected returns set to top 20 times if the company meets certain milestones.

Apposite first backed the non-surgical lifting and tightening treatments specialist in 2009 and was its second largest investor. Under the terms of the deal, it will receive $600m plus further milestone payments.

Since it was backed by Apposite, the company has seen its revenues jump 14 times with more than $100m expected in 2014.

Ulthera has the first and still the only energy-based device to receive US FDA clearance for a non-invasive aesthetic lift indication.

Apposite managing partner David Porter said, “Ulthera’s ground breaking technology which produced excellent clinical results, the hard work and talent of its management team, and the highly effective Board has enabled the company to become a major force in the aesthetic market.

“We have seen astonishing growth driven by product development, international expansion and a significant increase in the workforce.”

Last year Apposite exited portfolio company Zonare Medical Systems to China’s Mindray Medical International.

Copyright © 2014 AltAssets